Stock Traders Buy Large Volume of ADMA Biologics Call Options (NASDAQ:ADMA)

ADMA Biologics, Inc. (NASDAQ:ADMA) was the recipient of unusually large options trading on Monday. Investors acquired 11,474 call options on the stock. This represents an increase of 539% compared to the average volume of 1,797 call options.

Analysts Set New Price Targets

Several brokerages recently issued reports on ADMA. HC Wainwright raised their target price on shares of ADMA Biologics from $18.00 to $26.00 and gave the stock a “buy” rating in a report on Friday, November 8th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $20.00 price target on shares of ADMA Biologics in a research report on Friday, September 20th. Finally, Raymond James boosted their price objective on ADMA Biologics from $18.00 to $25.00 and gave the company a “strong-buy” rating in a report on Friday, November 8th.

ADMA Biologics Stock Performance

ADMA opened at $21.78 on Wednesday. The firm has a fifty day moving average price of $18.22 and a 200 day moving average price of $14.06. ADMA Biologics has a 1 year low of $3.60 and a 1 year high of $23.64. The stock has a market cap of $5.08 billion, a P/E ratio of 78.75 and a beta of 0.64. The company has a debt-to-equity ratio of 0.74, a current ratio of 6.87 and a quick ratio of 2.80.

ADMA Biologics (NASDAQ:ADMA) last posted its earnings results on Thursday, November 7th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.13 by $0.02. ADMA Biologics had a net margin of 17.80% and a return on equity of 59.29%. The business had revenue of $119.84 million for the quarter, compared to analyst estimates of $107.25 million. During the same period in the prior year, the company posted $0.01 EPS. Equities research analysts anticipate that ADMA Biologics will post 0.51 earnings per share for the current year.

Insider Buying and Selling

In other news, COO Kaitlin M. Kestenberg-Messina sold 24,150 shares of the company’s stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $16.90, for a total transaction of $408,135.00. Following the transaction, the chief operating officer now owns 449,088 shares in the company, valued at $7,589,587.20. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other news, COO Kaitlin M. Kestenberg-Messina sold 24,150 shares of ADMA Biologics stock in a transaction on Friday, August 30th. The shares were sold at an average price of $16.90, for a total transaction of $408,135.00. Following the completion of the sale, the chief operating officer now directly owns 449,088 shares in the company, valued at approximately $7,589,587.20. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Adam S. Grossman sold 236,889 shares of the company’s stock in a transaction on Monday, August 26th. The shares were sold at an average price of $17.69, for a total value of $4,190,566.41. Following the completion of the transaction, the chief executive officer now directly owns 2,059,726 shares in the company, valued at approximately $36,436,552.94. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 466,900 shares of company stock worth $8,224,121 in the last ninety days. 3.70% of the stock is owned by insiders.

Institutional Trading of ADMA Biologics

A number of institutional investors and hedge funds have recently made changes to their positions in the business. D. E. Shaw & Co. Inc. grew its stake in ADMA Biologics by 26.8% in the 2nd quarter. D. E. Shaw & Co. Inc. now owns 6,824,517 shares of the biotechnology company’s stock valued at $76,298,000 after acquiring an additional 1,442,799 shares during the period. Assenagon Asset Management S.A. increased its stake in shares of ADMA Biologics by 2.7% during the third quarter. Assenagon Asset Management S.A. now owns 3,474,455 shares of the biotechnology company’s stock worth $69,454,000 after purchasing an additional 92,281 shares in the last quarter. Driehaus Capital Management LLC raised its position in shares of ADMA Biologics by 17.3% during the 2nd quarter. Driehaus Capital Management LLC now owns 3,028,667 shares of the biotechnology company’s stock worth $33,860,000 after purchasing an additional 447,743 shares during the last quarter. Renaissance Technologies LLC lifted its stake in ADMA Biologics by 28.7% in the 2nd quarter. Renaissance Technologies LLC now owns 2,582,135 shares of the biotechnology company’s stock valued at $28,868,000 after buying an additional 575,100 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its holdings in ADMA Biologics by 11.6% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 2,401,533 shares of the biotechnology company’s stock worth $48,007,000 after buying an additional 249,412 shares during the last quarter. 75.68% of the stock is currently owned by hedge funds and other institutional investors.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.